TY - JOUR
T1 - Treatment of axial spondyloarthritis
T2 - an update
AU - Danve, Abhijeet
AU - Deodhar, Atul
N1 - Funding Information:
The authors would like to thank Kirsten McGorty PharmD (Yale New Haven Hospital) for the help with Tables 1 and 2 and Figs 2 and 3.
Funding Information:
A. Danve: research grants from Novartis, Lilly; advisory boards at Janssen, AbbVie and Amgen; member of the Spondyloarthritis Research and Treatment Network and the Assessment of Spondyloarthritis International Society. A. Deodhar: research grants from AbbVie, Celgene, Eli Lilly, Glaxo Smith Kline, Novartis, Pfizer and UCB; advisory boards and consulting at AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, Glaxo Smith Kline, Janssen, MoonLake, Novartis, Pfizer and UCB; member of the Spondyloarthritis Research and Treatment Network, the Assessment of Spondyloarthritis International Society and the Scientific Advisory Board of Spondylitis Association of America.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/4
Y1 - 2022/4
N2 - Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the past two decades. With advances in the discernment of immunopathogenesis of this disease, new therapies have become available, which are associated with substantial improvement in symptoms, signs and quality of life. The four broad categories of approved treatment options are physical therapy and exercise (which have been known to be beneficial for millennia), NSAIDs (since the 1950s), TNF inhibitors (first FDA approval in 2003) and IL-17 inhibitors (first FDA approval in 2016). In addition, there have been a host of new developments in the axSpA field, including new treatment guidelines, the FDA approval of three biologic DMARDs to treat non-radiographic axSpA, the FDA and EMA approval of Janus kinase (JAK) inhibitors for ankylosing spondylitis, new data on the effect of biologic DMARDs on structural progression in ankylosing spondylitis, strategy trials on tapering or stopping TNF inhibitors in patients in remission, trials of treat-to-target strategy in axSpA, and several new molecules in phase III studies. This Review explores the developments in the management of axSpA.
AB - Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the past two decades. With advances in the discernment of immunopathogenesis of this disease, new therapies have become available, which are associated with substantial improvement in symptoms, signs and quality of life. The four broad categories of approved treatment options are physical therapy and exercise (which have been known to be beneficial for millennia), NSAIDs (since the 1950s), TNF inhibitors (first FDA approval in 2003) and IL-17 inhibitors (first FDA approval in 2016). In addition, there have been a host of new developments in the axSpA field, including new treatment guidelines, the FDA approval of three biologic DMARDs to treat non-radiographic axSpA, the FDA and EMA approval of Janus kinase (JAK) inhibitors for ankylosing spondylitis, new data on the effect of biologic DMARDs on structural progression in ankylosing spondylitis, strategy trials on tapering or stopping TNF inhibitors in patients in remission, trials of treat-to-target strategy in axSpA, and several new molecules in phase III studies. This Review explores the developments in the management of axSpA.
UR - http://www.scopus.com/inward/record.url?scp=85126041758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126041758&partnerID=8YFLogxK
U2 - 10.1038/s41584-022-00761-z
DO - 10.1038/s41584-022-00761-z
M3 - Review article
C2 - 35273385
AN - SCOPUS:85126041758
SN - 1759-4790
VL - 18
SP - 205
EP - 216
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
IS - 4
ER -